Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165649 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KDM4ECHRM3LMNAALDH1A1 | |
| SCHEMBL3157596 | 0.87 | ALDH1A1 (0.45) | SMN1; SMN2KDM4ELMNAALDH1A1PKM | |
| SCHEMBL3167442 | 0.78 | MAPT (0.47) | SMN1; SMN2KDM4ELMNAALDH1A1HTT | |
| SCHEMBL3164126 | 0.76 | KDM4E (0.46) | SMN1; SMN2KDM4ELMNAALDH1A1CYP2C19 | |
| SCHEMBL3166045 | 0.72 | RAB9A (0.53) | SMN1; SMN2KDM4ELMNAALDH1A1HTT | |
| SCHEMBL3163132 | 0.70 | KMT2A (0.48) | SMN1; SMN2KDM4ELMNAALDH1A1HTT | |
| SCHEMBL3163782 | 0.70 | RAB9A (0.51) | SMN1; SMN2KDM4ELMNAALDH1A1HTT | |
| SCHEMBL4807243 | 0.70 | PARP1 (0.47) | SMN1; SMN2LMNAALDH1A1HTTGAA | |
| SCHEMBL3157325 | 0.70 | RORC (0.41) | SMN1; SMN2LMNAGAAL3MBTL1MAPK1 | |
| SCHEMBL3162800 | 0.69 | XIAP (0.45) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716128-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2010-03-31 | — | — | EP | claimed |
| US-7348347-B2 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | claimed |
| JP-2007522171-A | — | — | 2007-08-09 | — | — | JP | claimed |
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2007-02-01 | — | — | US | claimed |
| EP-1716128-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2006-11-02 | — | — | EP | claimed |
| WO-2005077924-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2005-08-25 | — | — | WO | claimed |
| EP-1716128-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-7348347-B2 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
| EP-1716128-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077924-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | TPH2, HTR6, TPH1 | SMN1; SMN2 1583/4885KDM4E 1046/4885CHRM3 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.